Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-label, Controlled Phase Ⅱ Clinical Trial of Ivonescimab Combined With Chemotherapy Versus Penpulimab Combined With Chemotherapy for Neoadjuvant Treatment of Non-small Cell Lung Cancer (NSCLC)

NCT07086326 is registered in ClinicalTrials.gov with Yang Fan, MD as lead sponsor.

NCT NCT07086326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07086326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-label, Controlled Phase Ⅱ Clinical Trial of Ivonescimab Combined With Chemotherapy Versus Penpulimab Combined With Chemotherapy for Neoadjuvant Treatment of Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Yang Fan, MD
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
December 30, 2027
Enrollment
164 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ak112, bispecific antibody, immunotherapy, neoadjuvant therapy, nsclc